<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473911</url>
  </required_header>
  <id_info>
    <org_study_id>19-336</org_study_id>
    <nct_id>NCT04473911</nct_id>
  </id_info>
  <brief_title>Haplo Peripheral Blood Sct In GVHD Prevention</brief_title>
  <official_title>Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zachariah Michael DeFilipp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regimmune Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in
      people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic
      syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML),
      chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood
      stem cell transplantation.

        -  GVHD is a condition in which cells from the donor's tissue attack the organs.

        -  RGI-2001 is an investigational treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a pilot study in subjects undergoing reduced-intensity haploidentical peripheral
           blood stem cell transplantation who will receive graft-versus-host disease prevention
           with post-transplant cyclophosphamide, followed by sirolimus, mycophenolate mofetil, and
           RGI-2001.

        -  The research study procedures include screening for eligibility and study treatment
           including evaluations and follow up visits.

        -  The standard of care drugs of fludarabine, cyclophosphamide, melphalan, radiation,
           sirolimus, and mycophenolate mofetil are all FDA approved.

             -  Eligible Participants will be placed in 1 of 2 groups, per physicians discretion:

             -  Regimen #1 :

                  -  Before stem cell transplant:Fludarabine + Cyclophosphamide + Radiation

                  -  After stem cell transplant: Cyclophosphamide + Sirolimus +Mycophenolate
                     mofetil + RGI-2001

             -  Regimen #2

                  -  Before stem cell transplant: fludarabine + melphalan + radiation

                  -  After stem cell transplant: cyclophosphamide + sirolimus +Mycophenolate
                     mofetil + RGI-2001

        -  A total of 20 participants will be enrolled to this trial

        -  The U.S. Food and Drug Administration (FDA) has not approved RGI-2001 as a treatment for
           any disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients achieving successful donor engraftment</measure>
    <time_frame>60 Days</time_frame>
    <description>(absolute neutrophil count &gt; 500/uL and ≥ 90% donor cell chimerism)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>100-day non-relapse mortality (NRM) rate.</measure>
    <time_frame>100 Days</time_frame>
    <description>The regimen will be considered as safe if 100d NRM rate is &lt;=5%, and not safe if 100d NRM rate is ≥25%.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>GVHD</condition>
  <condition>AML</condition>
  <condition>ALL</condition>
  <condition>MDS</condition>
  <condition>MPN</condition>
  <condition>CMML</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Blood Stem Cell Transplant Failure</condition>
  <condition>Graft Vs Host Disease</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Disorder</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Chemosensitive Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician
Pre- stem cell transplant:
Fludarabine predetermined dose, intravenously, 4 times per cycle
Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Total body irradiation (TBI) once during treatment cycle
Post stem cell transplant:
Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral.
Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
RGI-2001: IV, predetermined dose, weekly to 6 total doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-. Patients who meet eligibility criteria for the study will subsequently be enrolled for treatment. Two reduced intensity regimens will be allowed, according to the choice of the treating physician
Pre- stem cell transplant:
Fludarabine predetermined dose, intravenously 3 times per cycle
Melphalan, infusion, determined dosage, once per cycle
Total body irradiation (TBI) once per cycle.
Post stem cell transplant
Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral:
Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle
RGI-2001: IV, predetermined dose, weekly to 6 total doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLUDARABINE</intervention_name>
    <description>predetermined dose, intravenously, a predetermined times per cycle Given in both pre stem cell and post stem cell cycles</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Fludara®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYCLOPHOSPHAMIDE</intervention_name>
    <description>◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TBI</intervention_name>
    <description>Total body irradiation (TBI) once per cycle.</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan, infusion, determined dosage, once per cycle</description>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Alkeran®</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>Phenylalanine Mustard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus: Predetermined dosage, predetermined number of time in cycle, oral: Please note that doses of sirolimus can be adjusted at the treating physician's discretion given the multiple drugs and other situations which affect its metabolism</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>◦Mycophenolate mofetil, oral or iv(predetermined dose or IV TID (based upon actual body weight), at predetermined times per cycle</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RGI-2001</intervention_name>
    <description>IV, predetermined dose, weekly to 6 total doses</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYCLOPHOSPHAMIDE</intervention_name>
    <description>◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion</description>
    <arm_group_label>Regimen 1: Fludarabine, Cyclophosphamide, and TBI</arm_group_label>
    <arm_group_label>Regimen 2: Fludarabine, Melphalan, and TBI</arm_group_label>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥ 18 and ≤ 80 years old

          -  Diagnosis of hematological malignancy:

               -  Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in morphologic
                  complete remission

               -  Myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), or chronic
                  myelomonocytic leukemic (CMML) with &lt; 5% blasts in blood or bone marrow

               -  Chemosensitive Hodgkin lymphoma (HL) or Non-Hodgkin lymphoma (NHL)

          -  Patients must be undergoing haploidentical allogeneic hematopoietic cell
             transplantation, defined as 1st or 2nd degree relative with at least 5/10 matching at
             HLA-A, -B, -C, DR, and DQ.

          -  ECOG performance status ≤2

          -  Patients with adequate physical function as measured by:

               -  Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening
                  fraction &gt;25%

               -  Hepatic:

                    -  Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert's syndrome or
                       hemolysis

                    -  ALT, AST, and Alkaline Phosphatase &lt; 5 x ULN

               -  Renal: Serum creatinine within normal range, or if serum creatinine is outside
                  normal range, then renal function (measured or estimated creatinine clearance or
                  GFR) ≥ 40mL/min/1.73m2

               -  Pulmonary: DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior allogeneic hematopoietic stem cell transplantation. (Patients may have received
             a prior autologous hematopoietic stem cell transplant.)

          -  Participants who are receiving any other investigational agents within 14 days prior
             to RGI-2001 dosing. Thus, participants must stop investigational agents by Day -9
             prior to transplant.

          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure, recent myocardial infarction or stroke, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  Patients with active or uncontrolled bacterial, viral, or fungal infection(s)
             requiring systemic therapy.

          -  Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.

          -  Pregnant and breast-feeding women are ineligible because they are not eligible for
             hematopoietic stem cell transplantation.

          -  HIV-positive participants and patients with active Hepatitis B or C are ineligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachariah DeFilipp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zachariah DeFilipp, MD</last_name>
    <phone>(617) 726-5765</phone>
    <email>zdefilipp@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Zachariah DeFilipp, MD</last_name>
      <phone>617-726-5765</phone>
    </contact>
    <investigator>
      <last_name>Zachariah DeFilipp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Zachariah Michael DeFilipp</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <keyword>MPN</keyword>
  <keyword>CMML</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non Hodgkin Lymphoma</keyword>
  <keyword>Blood Stem Cell Transplant Failure</keyword>
  <keyword>Graft Vs Host Disease</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Myeloproliferative Disorder</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>Chemosensitive Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to, please contact the Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

